Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study

References

• Landgren O, Rajkumar SV. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res. 2016;22(22):5428–5433. doi:10.1158/1078-0432.CCR-16-086628151710
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863–2869.26240224
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2018;93:981–1114.30400719
   PubMed Web of Science ®Google Scholar
• Kastritis E, Terpos E, Moulopoulos L, et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia. 2013;27:947–953.23183429
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Updated diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annual Meeting. 2016;35:e418–23.
   PubMedGoogle Scholar
• Acquah ME, Hsing AW, McGuire V, Wang S, Birmann B, Dei-Adomakoh Y. Presentation and survival of multiple myeloma patients in Ghana: a review of 169 cases. Ghana Med J. 2019;53:52–58.31138944
   PubMedGoogle Scholar
• Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785–789.17942755
   PubMed Web of Science ®Google Scholar
• Tian C, Wang L, Wu L, et al. Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis. Biosci Rep. 2018;38.
   Web of Science ®Google Scholar
• González-Calle V, Slack A, Keane N, et al. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Ann Hematol. 2018;97:1453–1462.29623394
   PubMed Web of Science ®Google Scholar
• Lakshman A, Rajkumar SV, Buadi FK, Binder M. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. 2018;8:59.
   Google Scholar
• Ryšavá R. AL amyloidosis: advances in diagnostics and treatment. Nephrol Dialysis Transplant. 2018;34.
   PubMed Web of Science ®Google Scholar
• Desport E, Bridoux F, Sirac C, et al. AL Amyloidosis. Orphanet J Rare Dis. 2012;7:54.22909024
   PubMed Web of Science ®Google Scholar
• Vela-Ojeda J, García-Ruiz Esparza MA, Padilla-González Y, et al. Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor. Ann Hematol. 2009;88:59–66.18648809
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751–3757.15365071
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989–995.22331953
   PubMed Web of Science ®Google Scholar
• Vela-Ojeda J, Esparza GR, Padilla-González Y, et al. Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor. Ann Hematol. 2009;88:59–66.18648809
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, Lazarus HM. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? Bone Marrow Transplant. 2006;38:7–15.16715110
   PubMed Web of Science ®Google Scholar
• Desikan KR, Dhodapkar MV, Hough A, et al. Incidence and Impact of Light Chain Associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma. 1997;27:315–319.9402328
   PubMed Web of Science ®Google Scholar
• Madan S, Dispenzieri A, Lacy MQ, et al. Clinical features and treatment response of Light Chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clinic Proc. 2010;85:232–238.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e48.25439696
   PubMed Web of Science ®Google Scholar
• Grateau G, Solomon A, Sezer O, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid an Amyloidosis, Tours, France, 18–22 April 2004. Clinica Chimica Acta Int J Clin Chem. 2005;356:1–8.
   PubMedGoogle Scholar
• Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46.27511158
   PubMed Web of Science ®Google Scholar
• Rijswijk MHV. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arth Rheumatol. 2014;54:2015–2021.
   Google Scholar
• Zhang CL, Qiu Y, Shen KN, et al. Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells. Leuk Res. 2019;81:19–24.30981853
   PubMed Web of Science ®Google Scholar
• Tovar N, Rodríguez-Lobato LG. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome. 2018;25:79–85.
   Google Scholar
• Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med. 1991;324:1845–1851.1904132
   PubMed Web of Science ®Google Scholar
• Huang X, Wang Q, Jiang S, Chen W, Zeng C, Liu Z. The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients. Clin Kidney J. 2014;8:120–126.25713722
   PubMedGoogle Scholar
• Sidiqi MH, Aljama MA, Muchtar E, et al. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. 2018;2:769–776.
   Google Scholar
• Lilleness B, Ruberg FL. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. 2019;133:215–223.
   Google Scholar
• Tomlinson R, Matigian N, Mollee P. Validation of the Boston University staging system in AL amyloidosis. Amyloid. 2019;26:125–127.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Dimopoulos MA. Prognosis and risk assessment in AL amyloidosis – there and back again. Br J Haematol. 2017;177:343–345.28437006
   PubMed Web of Science ®Google Scholar
• Gertz M. Amyloidosis: prognosis and treatment. Semin Arthritis Rheum. 1994;24:124–138.7839154
   PubMed Web of Science ®Google Scholar
• Muchtar E, Dispenzieri A, Leung N. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. 2018;32:2240–2249.
   Google Scholar
• Meng X, Juan HE, Yan LI, et al Comparative Study of the curative effects of BD Regimen and VAD regimen in the treatment of multiple myeloma. J China Med Univ. 2011;40:352–356.
   Google Scholar
• Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020;95:848–860.32267020
   PubMed Web of Science ®Google Scholar